NAGAILEBEN Rebounds on Return to Operating Profit Growth in December-February Period Driven by Core Market Recovery

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

Fri Apr 3, 2026 10:12 am JST Catalyst

NAGAILEBEN Co.,Ltd. <7447> rebounded. The company announced its consolidated financial results for the interim period ended February after the close of trading on the 2nd, reporting sales of \7.861 billion (up 0.2% year-on-year), operating profit of \1.381 billion (down 7.9%), and net profit of \1.014 billion (down 4.5%), marking higher revenue but lower profits. However, operating profit for the second quarter from December 2025 to February 2026 increased 5.3%, attracting buying interest in response to the recovering earnings trend.

The recovery was driven by the core markets of healthcare wear and doctor wear, which had experienced double-digit revenue declines in the first quarter but returned to a recovery trend in the second quarter as renewal contract orders progressed as planned and major renewal projects carried over from the previous period commenced. The price revision implemented in February also contributed favorably as it has been steadily absorbed by the market.

The company maintained its full-year earnings forecast for the fiscal year ending August 2026, projecting sales of \180 billion (up 6.0% from the previous year), operating profit of \40.25 billion (up 12.3%), and net profit of \29 billion (up 12.7%).

Source: MINKABU PRESS